Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.47%
#2 Status Status +17.94%
#3 GoPlus Security GoPlus Security +14.03%
#4 Ontology Gas Ontology Gas +11.14%
#5 Fake World Assets Fake World Assets +9.28%
#6 DMT-NAT DMT-NAT +9.09%
#7 o1.exchange o1.exchange +7.20%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nillion Nillion +7.03%
#10 Pons Pons +6.71%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Hisse Senetlerindeki Sıralama #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Hisse Fiyatı
$0.1502
Son senkronizasyon: 2024-11-04
Piyasa Değeri
$6.43M
Değişim (1 gün)
-5.45%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Renalytix Plc (RNLX)

Kategori

Healthcare
Renalytix Plc (RNLX) için Faaliyet Marjı
August 2026 itibarıyla Faaliyet Marjı TTM: -1,293.49%
Renalytix Plc şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -1,293.49%'dir. 2023 yılı sonunda şirketin faaliyet marjı -1,244.64% idi.
Renalytix Plc için 2018 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.